PACKAGE LEAFLET: INFORMATION FOR THE USER. ETOPOSIDE-TEVA 20 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION etoposide
|
|
- Alisha Norman
- 5 years ago
- Views:
Transcription
1 PACKAGE LEAFLET: INFORMATION FOR THE USER ETOPOSIDE-TEVA 20 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION etoposide Read all of this leaflet carefully before you start using this medicine because it contains important information for you. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor, pharmacist or nurse. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Etoposide-Teva is and what it is used for 2. What you need to know before you receive Etoposide-Teva 3. How to receive Etoposide-Teva 4. Possible side effects 5. How to store Etoposide-Teva 6. Contents of the pack and other information 1. WHAT ETOPOSIDE-TEVA IS AND WHAT IT IS USED FOR Etoposide-Teva is an anti-cancer drug for intravenous use, which is used to treat certain types of cancer. Etoposide-Teva is used in chemotherapy either alone, or in combination with other drugs. Etoposide-Teva is used for: testicular cancer lung cancer. 2. WHAT YOU NEED TO KNOW BEFORE YOU RECEIVE ETOPOSIDE-TEVA Do not receive Etoposide-Teva if you: are allergic to etoposide or any of the other ingredients of this medicine (listed in section 6) suffer from severe liver problems suffer from severe kidney problems have a weakened immune system and you have received a yellow fever vaccine or any other live vaccines (see section Other medicines and Etoposide-Teva). Etoposide-Teva must not be given by intra-cavitary injection (within a body cavity). Warnings and precautions Talk to your doctor or nurse before receiving Etoposide-Teva: if you have a low serum albumin level; the risk of toxicity caused by etoposide may be increased. if you have received other anticancer drugs or radiotherapy, your doctor should check the number of blood cells in your blood before treatment starts. if you have a bacterial infection, it should be treated before Etoposide Injection is given. in the case of the intravenous administration of Etoposide, paravenous injection must be carefully avoided. before the start of therapy, during the therapy, and before each course of treatment, a peripheral blood panel (white blood cells, platelets, haemoglobin), kidney and liver function should be checked, and neurological functions should be investigated.
2 if you are suffering from liver or kidney dysfunction, you should be treated with etoposide only if the dysfunction is attributable to the underlying condition. Furthermore, courses of therapy with etoposide should be carried out only if the peripheral nervous system is functioning normally. Tell your doctor immediately if you experience an allergic reaction with any of the following symptoms while receiving Etoposide-Teva: fever chills faster heart beat high blood pressure difficulty in breathing or wheezing shortness of breath. Your treatment will need to be stopped, and your doctor will need to treat these symptoms. Etoposide-Teva may cause your bone marrow to produce less blood cells. Therefore, your doctor will check on your blood cells regularly both during and after treatment. When your blood platelet count and white blood cell count become too low, your doctor will not start the next course until your blood cells have recovered sufficiently. Children There are no comprehensive studies of the use of etoposide in children. Other medicines and Etoposide-Teva Talk to your doctor if you are taking/receiving, have recently taken/received or might take/receive any of the following: immunosuppressant drugs (e.g. cyclosporine), which are usually used in organ transplantations to prevent rejection other drugs used for cancer treatment (e.g. cisplatin). The occurrence of acute leukaemia has been reported rarely in patients treated with Etoposide-Teva in combination with one of these drugs. antiepileptic drugs (e.g. phenytoin) blood thinning drugs (e.g. warfarin) vaccines (immunisations). Because your normal defence system may be suppressed by etoposide, your response to the vaccine may be decreased. Do NOT have any immunisations without your doctor s approval. anti-inflammatory drugs or painkillers (e.g. phenylbutazone, sodium salicylate and aspirin) anthracyclines (e.g. daunorubicin, doxorubicin, and epirubicin). Anthracyclines are a type of antibiotic used to treat many types of cancer. Please tell your doctor or nurse if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Pregnancy, breast-feeding and fertility Etoposide-Teva is not recommended if you are pregnant, planning to become pregnant or breast-feeding. However, your doctor may decide that the benefit you will receive from treatment with this medicine outweighs the risks to your unborn child. Female patients of child bearing age should use an effective method of contraception, e.g. the barrier method or condoms, to avoid getting pregnant during treatment, as the drug may cause serious birth defects. Male patients receiving treatment with Etoposide-Teva should also take adequate contraception precautions to ensure that their partner does not become pregnant while they are being treated or for up to 6 months after treatment and might want consider having their sperm frozen, as this medicine may cause impaired fertility.
3 Both male and female patients who are considering having a child after the treatment should discuss this with their doctor or nurse. Driving and using machines Your ability to drive or use machines may be impaired after being administered Etoposide-Teva. If you feel dizzy or sleepy after receiving this medicine, do NOT drive or use machines. Etoposide-Teva contains alcohol This medicine contains 24% w/v of ethanol (5 ml vial contains up to 1.2 g of alcohol; 25 ml vial contains up to 6 g of alcohol). This can be harmful for those suffering from alcoholism. This must also be taken into account in pregnant and breast-feeding women, children and high-risk groups such as patients with liver disease, brain injury or epilepsy. The amount of alcohol in this medicine may alter the effects of other medicines. Etoposide-Teva contains polysorbate 80 Polysorbate 80 may cause serious conditions in premature children such as liver and kidney failure, lung deterioration, reduction in platelets which increases risk of bruising or bleeding and a build-up of fluid of around the stomach. 3. HOW TO RECEIVE ETOPOSIDE-TEVA Etoposide-Teva will be given to you by a suitably experienced doctor or nurse and you will have regular tests to monitor your condition. Your medicine will then be given to you by slow intravenous infusion (an injection into the vein) usually over a 30 to 60 minute period. The required dose of Etoposide-Teva Concentrate for Solution for Infusion will be diluted with either 5% dextrose solution for injection or 0.9% saline solution to give the correct concentration. The duration of your treatment will be decided by the doctor. Your doctor may consider it necessary to give you a repeat course of Etoposide-Teva. Treatment may be repeated at intervals, as decided by your doctor, after you have recovered adequately from any toxicity. The dosage for Etoposide-Teva is estimated on your body surface area in square metres (m 2 ) calculated from your height and weight. The usual dose is: Adults (including the elderly) mg/m 2 intravenously, daily for five days. The treatment with Etoposide-Teva can be repeated after days, depending on your blood test results. Patients with kidney problems If you suffer from kidney problems, talk to your doctor. Your dose might need to be reduced. Children Use in Children is not recommended. If you receive more Etoposide-Teva than you should As a doctor or nurse will be giving you your medicine, it is unlikely that you will receive an incorrect dose. Tell your doctor or nurse if you have any concerns about the amount of medicine that you receive. If you have any further questions on the use of this product, ask your doctor or nurse.
4 4. POSSIBLE SIDE EFFECTS Like all medicines, Etoposide-Teva can cause side effects, although not everybody gets them. A few people may experience common serious side effects when taking this medicine. If you experience any of the following, tell your doctor immediately as your treatment will need to be stopped: a severe allergic reaction. The symptoms include chills, fever, faster heartbeat, high blood pressure, swelling of the face, mouth, and tongue, wheezing or difficulty breathing, shortness of breath, itchy skin, rash and/or hives. The following side effects have been reported: Very common (affecting more than 1 person in 10): blood test abnormalities caused by suppression of the bone marrow (myelosuppression), which can result in a low number of blood platelets, white or red blood cells, or anaemia abdominal pain, constipation, nausea and vomiting, lack or loss of appetite drug-induced liver damage reversible loss or thinning of hair (alopecia) abnormal pigmentation unusual tiredness or weakness (asthenia), feeling generally unwell. Common (affecting more than 1 person in 100 but less than 1 person in 10): disorders of the blood-forming bone marrow cells (acute leukaemia) heart attack, changes in heart rate (arrhythmia) dizziness, temporary low blood pressure when etoposide has been injected rapidly. To prevent this event, your doctor will administer Etoposide-Teva via a slow infusion over minutes. high blood pressure and flushing inflammation and ulceration of the mucous membranes of the digestive tract, diarrhoea rash, hives, or itching accidental leaking of the medicine into the surrounding tissue (extravasion) inflammation of veins (phlebitis), irritation and inflammation of soft tissue. Uncommon (affecting more than 1 person in 1,000 but less than 1 person in 100): constant numbness, tingling or pain in hands and feet (peripheral neuropathy). Rare (affecting more than 1 person in 10,000 but less than 1 person in 1,000): fits or spasms reversible loss of vision, inflammation of eye nerve unusual tiredness or fatigue (neurotoxicity) inflammation of the lungs or lung fibrosis difficulties swallowing, taste impairment, aftertaste rash, hives, itch, an acute skin condition with multiple red and purple blotches on the skin of the palms, soles, backs of the hands and feet and the upper surfaces of the arms and legs (Stevens- Johnson syndrome) an inflammatory skin reaction at bodily parts previously exposed to radiotherapy (radiation recall dermatitis). Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: ; Fax: Website: medsafety@hpra.ie.
5 By reporting side effects you can help provide more information on the safety of this medicine. 5. HOW TO STORE ETOPOSIDE TEVA You will not have to store this medicine. This medicine is stored under the responsibility of the specialist in appropriate premises. The following information is intended for the specialist only. Keep out of the sight and reach of children. Etoposide-Teva should be stored below 25 o C. It should be kept in the package or container supplied in order to protect from light. Do not transfer it to another container. Any solution showing signs of precipitation should not be used and should be discarded appropriately. Do not use Etoposide-Teva after the expiry date that is stated on the vial and outer packaging. The expiry date refers to the last day of that month. Storage instructions following dilution: On dilution with 0.9% sodium chloride injection or 5% dextrose, Etoposide-Teva 20 mg/ml is physically and chemically stable for 96 hours, however, from a microbiological point of view, the solution for infusion can only be used within 8 hours of preparation, when stored at room temperature (below 25C). Etoposide-Teva 20 mg/ml can be stored for 48 hours at room temperature (below 25C) following piercing of the rubber stopper. The vial should be pierced no more than three times during the 48 hour in-use storage period. Any remaining product after this time must be discarded appropriately. Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6. CONTENTS OF THE PACK AND OTHER INFORMATION What Etoposide-Teva contains The active ingredient is etoposide. The other ingredients are citric acid, anhydrous, polysorbate 80, absolute ethanol, macrogol 300. What Etoposide-Teva looks like and contents of the pack Etoposide-Teva Concentrate for Solution for Infusion is a clear, yellowish, slightly viscous solution in clear, colourless glass vials. Etoposide-Teva contains etoposide 20 mg/ml and is available as a sterile concentrate for solution for infusion, in 5 ml and 10 ml sterile multiple dose vials. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Marketing Authorisation holder: Teva Pharma B.V. Swensweg GA Haarlem Netherlands Manufacturer: Pharmachemie B.V. Swensweg RN Haarlem The Netherlands
6 This leaflet was last revised in December 2016.
PACKAGE LEAFLET: INFORMATION FOR THE USER Etoposide Accord 20 mg/ml Concentrate for Solution for Infusion Etoposide
PACKAGE LEAFLET: INFORMATION FOR THE USER Etoposide Accord 20 mg/ml Concentrate for Solution for Infusion Etoposide Read all of this leaflet carefully before you start taking this medicine because it contains
More informationLEUCOVORIN-TEVA 10 mg/ml CONCENTRATE FOR SOLUTION FOR INFUSION folinic acid as the calcium salt PACKAGE LEAFLET: INFORMATION FOR THE USER
LEUCOVORIN-TEVA 10 mg/ml CONCENTRATE FOR SOLUTION FOR INFUSION folinic acid as the calcium salt PACKAGE LEAFLET: INFORMATION FOR THE USER Read all of this leaflet carefully before you start using this
More informationThe name of this medicine is Vepesid. Each capsule contains etoposide (either 50 mg or 100 mg) as the active ingredient.
Package Leaflet: Information for the patient VEPESID SOFT CAPSULES 50 MG AND 100 MG (Etoposide) Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPackage leaflet: Information for the patient. ETOPOPHOS 100 mg Powder for Solution for Injection Etoposide phosphate
Package leaflet: Information for the patient ETOPOPHOS 100 mg Powder for Solution for Injection Etoposide phosphate Read all of this leaflet carefully before you start taking this medicine because it contains
More informationPackage leaflet: Information for the patient. Vyxeos 44 mg/100 mg powder for concentrate for solution for infusion daunorubicin and cytarabine
Package leaflet: Information for the patient Vyxeos 44 mg/100 mg powder for concentrate for solution for infusion daunorubicin and cytarabine Read all of this leaflet carefully before you start taking
More informationPackage leaflet: Information for the patient. VEPESID 50 mg and 100 mg capsules, soft Etoposide
Package leaflet: Information for the patient 50 mg and 100 mg capsules, soft Etoposide Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPackage leaflet: Information for the user. Portrazza 800 mg concentrate for solution for infusion necitumumab
Package leaflet: Information for the user Portrazza 800 mg concentrate for solution for infusion necitumumab This medicine is subject to additional monitoring. This will allow quick identification of new
More informationPackage leaflet: Information for the user. Topotecan Hospira 4 mg/4 ml concentrate for solution for infusion topotecan
Package leaflet: Information for the user Topotecan Hospira 4 mg/4 ml concentrate for solution for infusion topotecan Read all of this leaflet carefully before you start using this medicine because it
More informationPackage Leaflet: Information for the user. NAVELBINE 10 mg/ml concentrate for solution for infusion Vinorelbine (as tartrate)
Package Leaflet: Information for the user NAVELBINE 10 mg/ml concentrate for solution for infusion Vinorelbine (as tartrate) Read all of this leaflet carefully before you are given this medicine because
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Lartruvo 10 mg/ml concentrate for solution for infusion olaratumab This medicine is subject to additional monitoring. This will allow quick identification of new
More informationPackage leaflet: Information for the user Zinforo 600 mg powder for concentrate for solution for infusion Ceftaroline fosamil
Package leaflet: Information for the user Zinforo 600 mg powder for concentrate for solution for infusion Ceftaroline fosamil Read all of this leaflet carefully before you start using this medicine because
More informationPackage leaflet: Information for the user. Zavedos 5 mg and 10 mg Powder for Solution for Injection idarubicin hydrochloride
Package leaflet: Information for the user Zavedos 5 mg and 10 mg Powder for Solution for Injection idarubicin hydrochloride Read all of this leaflet carefully before you start taking this medicine because
More informationPackage leaflet: Information for the user
CSL Behring Package leaflet: Information for the user Alburex 5, 50 g/l, solution for infusion & Alburex 20, 200 g/l, solution for infusion Human albumin Read all of this leaflet carefully before you are
More informationPackage leaflet: Information for the user. HBVAXPRO 5 micrograms, suspension for injection in pre-filled syringe Hepatitis B vaccine (rdna)
Package leaflet: Information for the user HBVAXPRO 5 micrograms, suspension for injection in pre-filled syringe Hepatitis B vaccine (rdna) Read all of this leaflet carefully before you or your child is
More informationPackage leaflet: Information for the user. Exembol 1 mg/ml solution for infusion. argatroban monohydrate
Package leaflet: Information for the user Exembol 1 mg/ml solution for infusion argatroban monohydrate Read all of this leaflet carefully before you start using this medicine because it contains important
More informationPackage leaflet: Information for the user. Lidocaine Hydrochloride 1% w/v Solution for Injection Lidocaine Hydrochloride
Package leaflet: Information for the user Lidocaine Hydrochloride 1% w/v Solution for Injection Lidocaine Hydrochloride Read all of this leaflet carefully before you start using this medicine because it
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Pneumococcal Polysaccharide Vaccine
PACKAGE LEAFLET: INFORMATION FOR THE USER PNEUMOVAX 23 solution for injection in a vial Pneumococcal Polysaccharide Vaccine For adults and children 2 years and above. Read all of this leaflet carefully
More informationUser Package Leaflet for Treosulfan 5 g Powder for Solution for Injection or Infusion
User Package Leaflet for Treosulfan 5 g Powder for Solution for Injection or Infusion Please read this leaflet carefully, it is a summary of the information about treosulfan that could be important to
More informationPACKAGE LEAFLET: INFORMATION FOR THE PATIENT
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT Kopen Sugar Free 125mg/5ml and 250mg/5ml Powder for Oral Solution Phenoxymethylpenicillin Read all of this leaflet carefully before you start taking this medicine
More informationPackage leaflet: Information for the user. DaunoXome Injection 2mg/ml Concentrate for Solution for Infusion Daunorubicin
Package leaflet: Information for the user DaunoXome Injection 2mg/ml Concentrate for Solution for Infusion Daunorubicin Read all of this leaflet carefully before you start using this medicine because it
More information1. What Faslodex is and what it is used for
Package leaflet: Information for the user Faslodex 250 mg solution for injection Fulvestrant Read all of this leaflet carefully before you start using this medicine because it contains important information
More informationPackage leaflet: Information for the user. Elaprase 2 mg/ml concentrate for solution for infusion idursulfase
Package leaflet: Information for the user Elaprase 2 mg/ml concentrate for solution for infusion idursulfase This medicine is subject to additional monitoring. This will allow quick identification of new
More informationPerjeta Contains the active ingredient pertuzumab (rch)
Perjeta Contains the active ingredient pertuzumab (rch) Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Perjeta. It does not contain all the available
More informationHavrix Monodose Vaccine Hepatitis A Vaccine (Inactivated, adsorbed) ELISA Units/1 ml Suspension for Injection in a pre-filled syringe
GSK (logo) Package Leaflet: Information for the User Havrix Monodose Vaccine Hepatitis A Vaccine (Inactivated, adsorbed). 1440 ELISA Units/1 ml Suspension for Injection in a pre-filled syringe Read all
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion Docetaxel Accord 160 mg/8
More informationPackage leaflet: Information for the patient. Selenium 10 micrograms/ml concentrate for solution for infusion. Sodium selenite
Package leaflet: Information for the patient Selenium 10 micrograms/ml concentrate for solution for infusion Sodium selenite Read all of this leaflet carefully before you start using this medicine because
More informationPackage leaflet: Information for the user. HBVAXPRO 40 micrograms, suspension for injection Hepatitis B vaccine (rdna)
Package leaflet: Information for the user HBVAXPRO 40 micrograms, suspension for injection Hepatitis B vaccine (rdna) Read all of this leaflet carefully before you are vaccinated because it contains important
More informationPackage leaflet: Information for the patient. Zerbaxa 1 g / 0.5 g powder for concentrate for solution for infusion ceftolozane / tazobactam
Package leaflet: Information for the patient Zerbaxa 1 g / 0.5 g powder for concentrate for solution for infusion ceftolozane / tazobactam This medicine is subject to additional monitoring. This will allow
More informationPackage leaflet: Information for the user. /.../ 50 mg powder and solvent for solution for injection/infusion. melphalan
Package leaflet: Information for the user /.../ 50 mg powder and solvent for solution for injection/infusion melphalan Read all of this leaflet carefully before you start using this medicine because it
More informationPackage leaflet: Information for the patient. Gemcitabine 10 mg/ml, solution for infusion. gemcitabine
Package leaflet: Information for the patient Gemcitabine 10 mg/ml, solution for infusion gemcitabine Read all of this leaflet carefully before you are given this medicine because it contains important
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Taltz 80 mg solution for injection in pre-filled syringe ixekizumab This medicine is subject to additional monitoring. This will allow quick identification
More informationPackage leaflet: Information for the user. Burinex 5 mg Tablets bumetanide
Package leaflet: Information for the user Burinex 5 mg Tablets bumetanide Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Calcium Folinate 10 mg/ml Injection
PACKAGE LEAFLET: INFORMATION FOR THE USER Calcium Folinate 10 mg/ml Injection Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again.
More informationPackage leaflet: Information for the patient. Heparin Sodium BP 1000 IU/L in 0.9% w/v Sodium Chloride IV Infusion. Active substance: Heparin Sodium
Package leaflet: Information for the patient Heparin Sodium BP 1000 IU/L in 0.9% w/v Sodium Chloride IV Infusion Active substance: Heparin Sodium Read all of this leaflet carefully before you are given
More informationZofran syrup contains a medicine called ondansetron. This belongs to a group of medicines called anti-emetics.
Package Leaflet: Information for the User Zofran 4 mg/5 ml Syrup Ondansetron Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
More informationPackage leaflet: Information for the patient. Tranexamic Acid 100 mg/ml, Solution for Injection tranexamic acid
Package leaflet: Information for the patient Tranexamic Acid 100 mg/ml, Solution for Injection tranexamic acid Read all of this leaflet carefully before you are given this medicine because it contains
More informationPackage Leaflet: Information for the user
Package Leaflet: Information for the user ZOSTAVAX Powder and solvent for suspension for injection in a pre-filled syringe shingles (herpes zoster) vaccine (live) Read all of this leaflet carefully before
More informationPackage leaflet: Information for the user. Novastan 100 mg/ml concentrate for solution for infusion. argatroban monohydrate
Package leaflet: Information for the user 100 mg/ml concentrate for solution for infusion argatroban monohydrate Read all of this leaflet carefully before you start using this medicine because it contains
More informationPackage leaflet: Information for the user Venofer 20 mg iron /ml Solution for injection or concentrate for solution for infusion Iron Sucrose
Package leaflet: Information for the user 20 mg iron /ml Solution for injection or concentrate for solution for infusion Iron Sucrose This medicine is subject to additional monitoring. This will allow
More informationEloxatin Oxaliplatin concentrated solution for injection
Eloxatin Oxaliplatin concentrated solution for injection Consumer Medicine Information Please read this leaflet before you are given this medicine. What is in this leaflet This leaflet answers some common
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS. Ibuprofen
PACKAGE LEAFLET: INFORMATION FOR THE USER EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS Ibuprofen Read all of this leaflet carefully before you start taking Easofen Max Strength Tablets because it contains
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER Gardasil, suspension for injection in a pre-filled syringe Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed) Read all of this leaflet
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Menveo powder and solution for solution for injection Meningococcal Group A, C, W135 and Y conjugate vaccine Read all of this leaflet carefully before you or your
More informationPATIENT INFORMATION LEAFLET. DOTAREM mg/ml, solution for injection (Gadoteric acid)
PATIENT INFORMATION LEAFLET DOTAREM 279.32 mg/ml, solution for injection (Gadoteric acid) Read all this leaflet carefully before you start using this medicine because it contains important information
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Trulicity 0.75 mg solution for injection in pre-filled pen Trulicity 1.5 mg solution for injection in pre-filled pen dulaglutide This medicine is subject to
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Parsabiv 2.5 mg solution for injection Parsabiv 5 mg solution for injection Parsabiv 10 mg solution for injection etelcalcetide This medicine is subject to
More informationPackage leaflet: Information for the user. Cyramza 10 mg/ml concentrate for solution for infusion ramucirumab
Package leaflet: Information for the user Cyramza 10 mg/ml concentrate for solution for infusion ramucirumab This medicine is subject to additional monitoring. This will allow quick identification of new
More informationSuspension for injection in pre-filled syringe Diphtheria, tetanus and pertussis (acellular component) vaccine (adsorbed, reduced antigen content)
Package leaflet: Information for the user TdaPBooster Suspension for injection in pre-filled syringe Diphtheria, tetanus and pertussis (acellular component) vaccine (adsorbed, reduced antigen content)
More informationZofran tablets contain a medicine called ondansetron. This belongs to a group of medicines called anti-emetics.
Package Leaflet: Information for the User Zofran 4 mg or 8 mg Film coated Tablets Ondansetron Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationSibelium 5 mg Tablets flunarizine
J-C 2017 Sibelium 5 mg Tablets flunarizine PACKAGE LEAFLET: INFORMATION FOR THE USER Read all of this leaflet carefully before you start taking this medicine because it contains important information for
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen exenatide
PACKAGE LEAFLET: INFORMATION FOR THE USER Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen exenatide Read all of this leaflet carefully before you start
More informationPackage leaflet: Information for the patient. Konakion MM Ampoules 10mg/ml solution for injection and oral solution Phytomenadione (vitamin K 1 )
Package leaflet: Information for the patient Konakion MM Ampoules 10mg/ml solution for injection and oral solution Phytomenadione (vitamin K 1 ) Roche Read all of this leaflet carefully before you start
More informationPackage leaflet: Information for the patient. Histaclar 10 mg Film-coated Tablets loratadine
Package leaflet: Information for the patient Histaclar 10 mg Film-coated Tablets loratadine Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPackage leaflet: Information for the user. Cyanokit 5 g powder for solution for infusion hydroxocobalamin
Package leaflet: Information for the user Cyanokit 5 g powder for solution for infusion hydroxocobalamin Read all of this leaflet carefully before using this medicine because it contains important information
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. DUKORAL suspension and effervescent granules for oral suspension Cholera vaccine (inactivated, oral)
PACKAGE LEAFLET: INFORMATION FOR THE USER DUKORAL suspension and effervescent granules for oral suspension Cholera vaccine (inactivated, oral) Read all of this leaflet carefully before you start using
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER ZIRPINE 10mg TABLETS Cetirizine dihydrochloride
PACKAGE LEAFLET: INFORMATION FOR THE USER ZIRPINE 10mg TABLETS Cetirizine dihydrochloride Read all of this leaflet carefully because it contains important information for you. This medicine is available
More information1. What Octostim Nasal Spray is and what it is used for
Package Leaflet: Information for the User Octostim 1.5 mg/ml Nasal Spray Desmopressin acetate Read all of this leaflet carefully before you start using this medicine because it contains important information
More informationPackage Leaflet: Information for the User Zotron 4mg/2ml (ή 8mg/4ml) Solution for Injection or Infusion ondansetron
Package Leaflet: Information for the User Zotron 4mg/2ml (ή 8mg/4ml) Solution for Injection or Infusion ondansetron Read all of this leaflet carefully before you start taking this medicine because it contains
More informationPackage leaflet: Information for the user. Chirocaine mg/ml or 1.25 mg/ml solution for infusion For epidural use only.
Package leaflet: Information for the user Chirocaine 0.625 mg/ml or 1.25 mg/ml solution for infusion For epidural use only Levobupivacaine Read all of this leaflet carefully before you start taking this
More informationPackage leaflet: Information for the user. Tuberculin PPD RT23 "SSI" 2 T.U./0.1 ml, solution for injection Tuberculin PPD RT 23
Package leaflet: Information for the user Tuberculin PPD RT23 "SSI" 2 T.U./0.1 ml, solution for injection Tuberculin PPD RT 23 Read all of this leaflet carefully before you are skin tested because it contains
More informationPackage leaflet: Information for the user. Cefixime ABR 100 mg/5 ml powder for oral suspension Cefixime
Package leaflet: Information for the user Cefixime ABR 100 mg/5 ml powder for oral suspension Cefixime Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationPackage leaflet: Information for the user. Sebivo 600 mg film-coated tablets Telbivudine
Package leaflet: Information for the user Sebivo 600 mg film-coated tablets Telbivudine Read all of this leaflet carefully before you start taking this medicine because it contains important information
More information2 What you need to know before you use Zofran Suppositories
Package Leaflet: Information for the User Zofran 16 mg Suppositories ondansetron Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. AVAXIM, Suspension for injection in a pre-filled syringe Hepatitis A vaccine (inactivated, adsorbed)
PACKAGE LEAFLET: INFORMATION FOR THE USER AVAXIM, Suspension for injection in a pre-filled syringe Hepatitis A vaccine (inactivated, adsorbed) Read all of this leaflet carefully before you are vaccinated
More informationAll medicines have risks and benefits. Your doctor has weighed the risks of you being given Mabthera SC against the benefits expected for you.
New Zealand Consumer Medicine Information MABTHERA SC Rituximab 1400 mg solution for subcutaneous injection for non-hodgkin s Lymphoma and 1600mg solution for subcutaneous injection for chronic lymphocytic
More informationANBESOL TM Anaesthetic Antiseptic Oromucosal solution Lidocaine hydrochloride 0.90%w/w, Chlorocresol 0.10%w/w, Cetylpyridinium Chloride 0.
ANBESOL TM Anaesthetic Antiseptic Oromucosal solution Lidocaine hydrochloride 0.90%w/w, Chlorocresol 0.10%w/w, Cetylpyridinium Chloride 0.02%w/w PATIENT INFORMATION LEAFLET Read all of this leaflet carefully
More informationPackage leaflet: Information for the patient. Vimpat 10 mg/ml solution for infusion lacosamide
Package leaflet: Information for the patient Vimpat 10 mg/ml solution for infusion lacosamide Read all of this leaflet carefully before you start using this medicine because it contains important information
More informationPackage leaflet: Information for the user. ReoPro 2 mg/ml solution for injection or infusion. abciximab
Package leaflet: Information for the user ReoPro 2 mg/ml solution for injection or infusion abciximab Read all of this leaflet carefully before you start using this medicine because it contains important
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Lidocaine Accord 10 mg/ml solution for injection Lidocaine Accord 20 mg/ml solution for injection Lidocaine hydrochloride Read all of this leaflet carefully before
More informationPackage Leaflet: Information for the user. Prevenar 13 suspension for injection Pneumococcal polysaccharide conjugate vaccine (13 valent, adsorbed)
Package Leaflet: Information for the user Prevenar 13 suspension for injection Pneumococcal polysaccharide conjugate vaccine (13 valent, adsorbed) Read all of this leaflet carefully before you or your
More informationSome general information on hepatitis A infection is given at the end of this leaflet.
Package Leaflet: Information for the User Havrix Monodose Vaccine Suspension for injection in a pre-filled syringe Hepatitis A (inactivated) vaccine (adsorbed) Read all of this leaflet carefully before
More informationPackage leaflet: Information for the user. Bupivacaine 0.25% w/v, 0.5% w/v solution for injection Bupivacaine Hydrochloride
Package leaflet: Information for the user Bupivacaine 0.25% w/v, 0.5% w/v solution for injection Bupivacaine Hydrochloride Read all of this leaflet carefully before you start using this medicine because
More informationPackage leaflet: Information for the user. Tobramycin 40 mg/ml Solution for Injection tobramycin
Package leaflet: Information for the user Tobramycin 40 mg/ml Solution for Injection tobramycin Read all of this leaflet carefully before you start using this medicine because it contains important information
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Zoledronic Acid 4 mg/5 ml concentrate for solution for infusion. Zoledronic acid
PACKAGE LEAFLET: INFORMATION FOR THE USER Zoledronic Acid 4 mg/5 ml concentrate for solution for infusion Zoledronic acid Read all of this leaflet carefully before you start using this medicine because
More informationPackage leaflet: Information for the user. Poliomyelitis Vaccine (Inactivated) suspension for injection in pre-filled syringe
Package leaflet: Information for the user Poliomyelitis Vaccine (Inactivated) suspension for injection in pre-filled syringe Read all of this leaflet carefully before you or your child is vaccinated because
More informationTYPHIM Vi, Solution for injection
PACKAGE LEAFLET: INFORMATION FOR THE USER TYPHIM Vi, Solution for injection Purified Vi Capsular Polysaccharide of Salmonella typhi (Ty 2 Strain). Read all of this leaflet carefully before you are vaccinated
More information1 What Engerix B is and what it is used for
Package leaflet: Information for the user ENGERIX B 20 micrograms/1 ml, suspension for injection Hepatitis B (rdna) vaccine (adsorbed) (HBV) Read all of this leaflet carefully before you start receiving
More informationPackage leaflet: Information for patient
Package leaflet: Information for patient Apresoline Ampoules 20mg Powder for concentrate for solution for injection or infusion Hydralazine hydrochloride Read all of this leaflet carefully before you start
More informationPATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET Page 1 of 6 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Ganciclovir 500 mg Powder for Infusion * Read all of this leaflet carefully before you start taking this medicine
More informationเอกสารกาก บยาภาษาอ งกฤษ. AVAXIM 160 U Suspension for injection in a prefilled syringe Hepatitis A vaccine (inactivated, adsorbed)
เอกสารกาก บยาภาษาอ งกฤษ AVAXIM 160 U Suspension for injection in a prefilled syringe Hepatitis A vaccine (inactivated, adsorbed) Read all of this leaflet carefully before youstart using this medicine because
More informationPackage leaflet: Information for the user. Iron
Package leaflet: Information for the user Monover 100 mg/ml solution for injection/infusion This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
More informationPackage leaflet: Information for the patient. Paracetamol 10 mg/ml solution for infusion. Paracetamol
Package leaflet: Information for the patient Paracetamol Read all of this leaflet carefully before you are given this medicine because it contains important information for you. - Keep this leaflet. You
More informationPackage leaflet: Information for the patient. Lacosamide G.L. 10 mg/ml solution for infusion lacosamide
Package leaflet: Information for the patient Lacosamide G.L. 10 mg/ml solution for infusion lacosamide Read all of this leaflet carefully before you start using this medicine because it contains important
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Gemzar 200 mg powder for solution for infusion Gemzar 1000 mg powder for solution for infusion Gemcitabine
PACKAGE LEAFLET: INFORMATION FOR THE USER Gemzar 200 mg powder for solution for infusion Gemzar 1000 mg powder for solution for infusion Gemcitabine Read all of this leaflet carefully before you start
More informationPackage leaflet: Information for the user. Salofalk 3g gastro-resistant prolonged-release granules. Mesalazine
Package leaflet: Information for the user Salofalk 3g gastro-resistant prolonged-release granules Mesalazine Read all of this leaflet carefully before you start taking this medicine because it contains
More information2. What you need to know before you take DDAVP/Desmopressin Tablets
Package Leaflet: Information for the user DDAVP /Desmopressin 0.1mg Tablets Desmopressin Acetate Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. MYLOTARG 5 mg powder for concentrate for solution for infusion gemtuzumab ozogamicin
PACKAGE LEAFLET: INFORMATION FOR THE USER MYLOTARG 5 mg powder for concentrate for solution for infusion gemtuzumab ozogamicin This medicine is subject to additional monitoring. This will allow quick identification
More informationSodium Chloride 0.9% w/v Intravenous Infusion BP Solution for Infusion Sodium chloride
Package leaflet: Information for the user Sodium Chloride 0.9% w/v Intravenous Infusion BP Solution for Infusion Sodium chloride Read all of this leaflet carefully before using this medicine because it
More informationWhat is in this leaflet:
Package leaflet: Information for the user Gemcitabine 38mg/ml Concentrate for Solution for Infusion Gemcitabine Read all of this leaflet carefully, before you start receiving this medicine because it contains
More informationPackage leaflet: Information for the user. Lycimor 300 mg Hard Capsules Lymecycline (equivalent to 300mg of tetracycline base)
Package leaflet: Information for the user Lycimor 300 mg Hard Capsules Lymecycline (equivalent to 300mg of tetracycline base) Read all of this leaflet carefully before you start taking this medicine because
More informationGammaplex 2.5 g, 5 g, 10 g and 20 g 5% w/v solution for infusion human normal immunoglobulin
Package leaflet: Information for the user Gammaplex 2.5 g, 5 g, 10 g and 20 g 5% w/v solution for infusion human normal immunoglobulin Read all of this leaflet carefully before you start using this medicine
More informationPackage leaflet: Information for the user. HEPATECT CP 50 IU/ml solution for infusion. Human hepatitis B immunoglobulin for intravenous administration
: Information for the user HEPATECT CP 50 IU/ml solution for infusion Human hepatitis B immunoglobulin for intravenous administration Read all of this leaflet carefully before you start using this medicine
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Rhesonativ 750 IU/ml, solution for injection Human anti-d immunoglobulin Read all of this leaflet carefully before you start taking this medicine because it contains
More information1. What Miacalcic is and what it is used for
Package leaflet: Information for the user Miacalcic 100 IU/ml solution for injection and infusion Calcitonin (salmon, synthetic) Read all of this leaflet carefully before you start using this medicine
More informationPackage leaflet: Information for the user. HBVAXPRO 10 micrograms, suspension for injection in pre-filled syringe Hepatitis B vaccine (rdna)
Package leaflet: Information for the user HBVAXPRO 10 micrograms, suspension for injection in pre-filled syringe Hepatitis B vaccine (rdna) Read all of this leaflet carefully before you are vaccinated
More informationPackage Leaflet: Information for the user. TARGAXAN 550 mg film-coated tablets rifaximin
B. PACKAGE LEAFLET Package Leaflet: Information for the user TARGAXAN 550 mg film-coated tablets rifaximin Read all of this leaflet carefully before you start taking this medicine because it contains important
More information